Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move ... Novo picked up the new triple agonist, UBT251, from China-based United Biotechnology. The candidate, which is still in ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Ratio 8.371% announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary United Biotechnology and Novo Nordisk for UBT251, a triple agonist of the ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... Researchers believe the GLP-1 agonist market could triple over the next decade to over $150 billion. Where to invest $1,000 right now?

Novo Nordisk has experienced a 50% drop due to potential ... to develop and commercialize their UBT 251, a triple antagonist which targets GLP-1, GIP and glucagon receptors. The drug has shown ...